Dr Zimei Wu
PhD (Otago, Drug delivery), MSc (Chinal Pharmaceutical University; Pharmacokinetics)
Dr. Wu’s research interests lie primarily in the area of safe and effective drug delivery through injection. Her recent research focuses on developing strategies for ‘tumour-targeted delivery’ of small anticancer molecules, especially using ‘smart’ liposomes. She also researches dermal/transdermal drug delivery. At Auckland, she has attracted $NZ 1M as Principal Investigator in contestable research funding including a Marsden Fast-Start and a NZ-China Research Alliance Project (from MSI). Publications: https://www.researchgate.net/profile/Zimei_Wu
Dr Wu is the receipt of the 2009 NZ-China Scientist Exchange Scholarship from the Royal Society of New Zealand. She is President of the Controlled Release Society NZ Local Chapter (http://www.nzcrs.org.nz), and a Global CRS Young Scientists Committee member. Within the School she serves in the Education Committee with the aim to improve teaching quality and student amenities. She was honored with a 'Best Teacher" prize from her Pharmacy undergraduate students (2013).
Research | Current
- Preformulation underpinning formulation design
- Conventional and novel drug delivery systems
- Liposomal formualtion and clinical applications
- Injectable formulation of poorly water soluble drugs
Novel strategy to delivery hypoxia-activated prodrug to cancer cells. (as Principal Investigator) Funded by Royal Society of New Zealand (Marsden)
Novel drug delivery systems to improve anticancer chemotherapy. (as Principal Investigator) Funded by NZ Ministry of Science and Innovation. This project is a collaboration project with China Pharmaceutical University and China Ministry of Science and Technology.
New strategy to overcome multidrug resistance in cancer (as co-Investigator): funded by Cancer Society of New Zealand
Nanotechnology to improve oral absorption of rhein. (as Principal Investigator). Funded by New Zealand Pharmacy Education and Research Foundation. This project is a collaboration project with China Pharmaceutical University, was supported by Royal Society of New Zealand.
Teaching | Current
- Pharmaceutical sciences (to pharmacy undergraduate and postgraduate students): Pharmaceutics, Formulation and drug delivery, and Pharmacokinetics
(Dr) Grant Cave (main supervisor Prof Jamie Sleigh)
Saiful Azmi (main supervisor Dr Darren Svirskis)
Kamal Patel (main supervisor Dr Vijayalekshmi Sarojini)
Noor Tawfeet (with Dr Darren Svirskis)
NZ-China Scientists Exchange Award from the Royal Society of New Zealand. 2009
Pharmacy 311: Module leader for Hepatic and Renal Diseases
Pharmacy 750: Pharmaceutical Formulation (Postgraduate, 30pt)
Areas of expertise
Honorary Professor, School of Pharmacy, Binzhou Medical University, China. 2010
Technology for Industry Fellowship. NZFRST. 2002
Visiting Scholarship from China Pharmaceutical University, funded by University of Otago. 1999
Selected publications and creative works (Research Outputs)
- Kang, W., Svirskis, D., Sarojini, V., McGregor, A. L., Bevitt, J., & Wu, Z. (2017). Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An in vitro boron neutron capture therapy study. Oncotarget, 8 (22), 36614-36627. 10.18632/oncotarget.16625
Other University of Auckland co-authors: Darren Svirskis, Viji Sarojini
- Yang, M. M., Kanamala, M., Tang, M., & Wu, Z. (2017). pH-sensitive liposomes for intracellular and tumour targeted drug delivery. In B. R. Pearson (Ed.) Liposomes : historical, clinical and molecular perspectives (pp. 135-170). New York, United States: Nova Science Pub Inc..
- Kang, W., Svirskis, D., & Wu, Z. (2017). Liposome-based boron neutron capture therapy for brain glioma: Current and future perspectives. In B. R. Pearson (Ed.) Liposomes : historical, clinical and molecular perspectives (pp. 317-342). New York, United States: Nova Science Pub Inc..
Other University of Auckland co-authors: Darren Svirskis, Weirong Kang
- Reginald-Opar, J. N., Dean, J., & Wu, Z. (2017). Advancements in liposomes for targeted drug delivery against neurodegenerative diseases. In B. R. Pearson (Ed.) Liposomes : historical, clinical and molecular perspectives (pp. 97-134). New York, United States: Nova Science Pub Inc..
Other University of Auckland co-authors: Justin Dean
- Yang, M. M., Wilson, W. R., & Wu, Z. (2017). pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells. International Journal of Pharmaceutics, 516 (1-2), 323-333. 10.1016/j.ijpharm.2016.11.041
Other University of Auckland co-authors: William Wilson
- Zhang, W., Li, C., Baguley, B. C., Zhou, F., Zhou, W., Shaw, J. P., ... Liu, J. (2016). Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: How to reliably produce a biomimetic 3D model. Analytical biochemistry, 515, 47-54. 10.1016/j.ab.2016.10.004
Other University of Auckland co-authors: Bruce Baguley, John Shaw
- Afzal, A., Sarfraz, M., Wu, Z., Wang, G., & Sun, J. (2016). Integrated scientific data bases review on asulacrine and associated toxicity. Critical reviews in oncology/hematology, 104, 78-86. 10.1016/j.critrevonc.2016.05.013
- Xu, H., Paxton, J. W., & Wu, Z. (2016). Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. Pharmaceutical research, 33 (7), 1628-1637. 10.1007/s11095-016-1902-8